On August 29, 2018 Zymeworks Inc. (NYSE/TSX: ZYME), a clinical‑stage biopharmaceutical company developing multifunctional biotherapeutics, reported that management will present at the upcoming 13th Annual Wells Fargo Securities Healthcare Conference taking place September 5-6, 2018 in Boston, MA (Press release, Zymeworks, AUG 29, 2018, View Source [SID1234529121]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will provide a corporate update and present upcoming catalysts on Wednesday, September 5, 2018 at 3:35 p.m. ET. Interested parties can access a live webcast of the presentation via a link from Zymeworks’ website at View Source, which will also host a recorded replay available afterwards

On August 29, 2018 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, reported that it will participate in two panel discussions, at the 2018 Citi Biotech Conference in Boston. Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer will represent Mirati at the event (Press release, Mirati, AUG 29, 2018, View Source [SID1234529138]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Targeted Therapies Oncology – Aiming for the Bull’s Eye" Panel on Wednesday, September 5th at 3:15 p.m. ET/12:15 p.m. PT

"Landscape in Immuno-Oncology and Bi-Specific Antibodies" Panel on Thursday, September 6th at 9:00 a.m. ET/ 6:00 a.m. PT

The webcasts will be available through the "Investors" section of www.mirati.com, and a replay of the webcasts will be made available for 90 days following the event.

On August 29, 2018 OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, reported that John Lewicki, Ph.D., President and Chief Executive Officer of OncoMed, will provide a corporate update at two upcoming investor conferences (Press release, OncoMed, AUG 29, 2018, View Source [SID1234529239]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo Securities 2018 Healthcare Conference in Boston, MA on September 5, 2018 at 9:40 am Eastern Time
20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC in New York, NY on September 6, 2018 at 4:40 pm Eastern Time
To access the live webcasts and subsequent archived recordings of these and other company presentations, please visit OncoMed’s website at www.oncomed.com/invest/events.cfm. A replay of each presentation will be available for 30 days following the date of the event.

On August 29, 2018 Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company") (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, reported that Dr. Bassam Damaj, President & Chief Executive Officer, and Ryan Selhorn, Vice President, Chief Financial Officer, will present at the 2018 H.C. Wainwright 20th Annual Global Investment Conference, on Thursday, September 6, 2018 (Press release, Innovus Pharmaceuticals, AUG 29, 2018, View Source [SID1234529122]). They will present an update on the Company’s growing revenues, the launch of new products, its path to profitability and its other business plans.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Damaj and Mr. Selhorn will be meeting with members of the investment community during one-on-one meetings at the conference as well. The corporate presentation will be available for download on the Innovus Pharma web site (www.innovuspharma.com).

About Conference Presentation Time

Event: H.C. Wainwright 20th Annual Global Investment Conference

Date: Thursday, September 6, 2018

Time: 10:25 AM-10:50 AM EDT

Location: St. Regis New York at 2 E 55th St., New York, NY 10022

On August 29, 2018 Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, reported that Michael Taylor, Ph.D., President and Chief Executive Officer, will participate in a panel discussion on targeted therapies in oncology at Citi’s 13th Annual Biotech Conference on Wednesday, September 5, 2018 at 3:15 PM ET at the Four Seasons Hotel Boston (Press release, Deciphera Pharmaceuticals, AUG 29, 2018, View Source [SID1234529139]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.